Table 3 Summary of Ba/F3 cell... | American Society of Hematology

Table 3

Summary of Ba/F3 cell proliferation experiments

	Imatinib		Nilotinib		Dasatinib
	IC₅₀, nM	SEM	IC₅₀, nM	SEM	IC₅₀, nM	SEM
Ba/F3	> 2000	NA	> 2000	NA	> 100	NA
p210	406	51	34.3	2.8	2.53	0.49
Patient mutants
N231D	401	50	38.2	3.8	3.35	0.78
T212R	957	96	84.4	5.6	3.75	0.36
A196V	381	55	30.4	2.8	2.62	0.52
S154N	256	69	28.3	6.9	2.61	0.64
K84N	396	34	35.8	3.2	3.15	0.74
R47C	392	46	33.2	3.1	2.71	0.56
E123Q	510	33	35.7	3.6	1.98	0.18
N231I	340	70	38.2	5.8	2.24	0.33
G144E	373	44	39.1	3.7	2.89	0.39
Activating mutants
Abl PP	378	72	49.0	4.0	3.86	1.05
K51A	433	68	38.0	5.5	4.00	1.21
W99A	423	137	45.3	137.1	4.18	0.97
Y139D	430	71	45.7	5.8	5.48	2.20
In vitro screen mutants
T224A	559	66	39.1	2.7	2.57	0.30
T212R double mutants
E275K	1343	134	116.5	16.4	3.19	0.36
T212R/E275K	∼ 2000	NA	176.3	10.4	4.67	1.39
T212R/S154N	403	73	36.6	1.8	1.79	0.19

	Imatinib		Nilotinib		Dasatinib
	IC₅₀, nM	SEM	IC₅₀, nM	SEM	IC₅₀, nM	SEM
Ba/F3	> 2000	NA	> 2000	NA	> 100	NA
p210	406	51	34.3	2.8	2.53	0.49
Patient mutants
N231D	401	50	38.2	3.8	3.35	0.78
T212R	957	96	84.4	5.6	3.75	0.36
A196V	381	55	30.4	2.8	2.62	0.52
S154N	256	69	28.3	6.9	2.61	0.64
K84N	396	34	35.8	3.2	3.15	0.74
R47C	392	46	33.2	3.1	2.71	0.56
E123Q	510	33	35.7	3.6	1.98	0.18
N231I	340	70	38.2	5.8	2.24	0.33
G144E	373	44	39.1	3.7	2.89	0.39
Activating mutants
Abl PP	378	72	49.0	4.0	3.86	1.05
K51A	433	68	38.0	5.5	4.00	1.21
W99A	423	137	45.3	137.1	4.18	0.97
Y139D	430	71	45.7	5.8	5.48	2.20
In vitro screen mutants
T224A	559	66	39.1	2.7	2.57	0.30
T212R double mutants
E275K	1343	134	116.5	16.4	3.19	0.36
T212R/E275K	∼ 2000	NA	176.3	10.4	4.67	1.39
T212R/S154N	403	73	36.6	1.8	1.79	0.19

NA indicates not applicable.